Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Many components of the Wnt pathway are theoretically targets for new drug discovery. Selecting a tissue-appropriate target may be an important consideration in order to limit toxicity.

We know today that Wnt and a handful of other signalling systems (Notch, Hedgehog, TGFβ (transforming growth factor-β)–BMP (bone morphogenetic protein) and receptor tyrosine kinases) are major ...

Background Development of diffuse-type gastric cancer (DGC) starts with intramucosal lesions that are primarily composed of ...

To investigate the transcriptional program underscoring cell proliferation induced by thyroid hormone (T3), we used complementary DNA mircroarrays to survey the temporal expression profiles of ...

The aberrant expression of partner of NOB1 homolog (PNO1) is known to promote oncogenesis in the colorectum and the esophagus, but its involvement in ovarian cancer and the mechanisms behind it are ...

Surrozen will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs including development of new treatment options for retinopathies. Other ...

The Wnt signaling pathway is a conserved network that regulates cell proliferation, differentiation, and migration. It consists of the canonical Wnt/β-catenin pathway and non-canonical pathways ...

Boston (February 26, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib ...

Boston (March 13, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...